Fig. 2From: Discontinuing monoclonal antibodies targeting CGRP pathway after one-year treatment: an observational longitudinal cohort studyThe frequency of patients having at least 8 MMDs in the three months of mAbs anti-CGRP pathway discontinuation in CM and HFEM patientsBack to article page